Sector News

Leo Pharma’s dermatology innovation challenge gathers ideas focused on skin of color

November 1, 2020
Life sciences

Leo Pharma’s latest “hackathon” brought together scientists and entrepreneurs to find dermatology solutions for people of color.

The third “Hacking Dermatology Innovation Challenge” tasked participants to focus on the specific challenges faced by “patients with skin of color.” The partnership between Leo’s research and development unit and nonprofit skin advocacy group Advancing Innovation in Dermatology (AID)  named five winning teams over the weekend.

Research has shown that diagnosing skin of color can be more difficult because of darker pigmentation as well as differences in the way inflammation presents. The “Hacking Dermatology” contest that ran through Sunday hopes to help with the issue.

Some of the ideas Leo was looking for included shortening diagnostic delays, making diagnoses more accurate, offering better personalized care, making clinical trials more diverse and providing empowerment and education that could lead to equity in technology advancements, Michael Sierra, vice president of the Leo Science & Tech Hub, said.

MIT Hacking Medicine is also part of this year’s challenge. While this is the third “Hacking Dermatology” challenge, it’s the first time the challenge was completely virtual due to the COVID-19 pandemic.

“What’s really cool about entrepreneurs and scientists is that most of us are introverts, right, so working in a virtual setting isn’t the biggest challenge. We’ve seen quite a good turnout,” Sierra said.

The three-day event began with a pitch session. Contributors then presented and competed over two days, with the winner announced Oct. 25.

The winning teams received $15,000 in grants and a chance to move to an advanced challenge with another $25,000 prize. The teams are mentored by volunteers from a variety of backgrounds and get access to resources that could potentially bring the winning projects to life.

The project was born in 2018 after Leo brought together key opinion leaders and scientists to consider innovation challenges in the field. Hacking Dermatology was created as a way to help healthcare professionals, entrepreneurs and others solve the real problems they’ve discovered, William Ju, M.D., one of the challenge founders and president and founder of AID, said.

“You can come to look and promote your idea, refine it, find key members and move it forward into something that is very tangible,” he said.

Over the past few years, Leo Pharma has purchased dermatology businesses including Bayer’s prescription unit and Astellas’ portfolio. Leo also markets plaque psoriasis drugs Enstilar and Taclonex.

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

September 19, 2021

From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year

Life sciences

This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.

September 19, 2021

Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalists

Life sciences

Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.

September 19, 2021

Research identifies possible link between antibiotic use and breast cancer growth

Life sciences

Researchers from the Quadram Institute and the University of East Anglia (UEA) discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew.

Send this to a friend